TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19904267

Group type: EXPERIMENTAL
Intervention: Gemcitabine (900 mg m(‐2) over 30 min), oxaliplatin (65 mg m(‐2)), and 5‐FU (1500 mg m(‐2) over 24 h) on days 1 and 8 of a 21‐day cycle
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Gemcitabine, oxaliplatin, and 5‐FU chemotherapy
Number of subjects: 72
Study: 16761242

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% ophthalmic solution in the morning
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% ophthalmic solution in the evening
Number of subjects: 92
Study: 15006586

Group type: EXPERIMENTAL
Intervention: Care suggestions with symptom data
Number of subjects: 720

Group type: COMPARATOR
Intervention: Care suggestions without symptom data (Control)
Number of subjects: 720
Study: 11430537

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.4-0.8 mg/h over 24 h
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neostigmine (crossover after 24 h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8968883

Group type: EXPERIMENTAL
Intervention: Adeno-associated virus (AAV) detection in genital swab specimens from women suspected of having HSV infection
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (other clinical samples)
Number of subjects: 61
Study: 8122736

Group type: EXPERIMENTAL
Intervention: Local anaesthetic solution at body temperature (37 +/- 1 degrees C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local anaesthetic solution at room temperature (22 +/- 1 degrees C)
Number of subjects: 40
Study: 3422548

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 15
Study: 28005403

Group type: EXPERIMENTAL
Intervention: Habit Reversal Training (HRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 40
Study: 26271928

Group type: EXPERIMENTAL
Intervention: Family@play intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 24129396

Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT) consisting of basal insulin detemir and premeal insulin aspart for 4 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT)
Number of subjects: 63
Study: 21406010

Group type: EXPERIMENTAL
Intervention: Chat line intervention for adolescents with type 1 diabetes
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (non-participants)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Comparison between chat line participants and control group
Number of subjects: 193
Study: 18715246

Group type: EXPERIMENTAL
Intervention: Prostate Cancer Prevention Trial (PCPT) risk calculator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRUS and prostate volume
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risk calculators comparison
Number of subjects: 0
Study: 18605232

Group type: EXPERIMENTAL
Intervention: Daonil (10 mg glyburide)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gen-Glybe (10 mg glyburide)
Number of subjects: 24
Study: 15360941

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI) using cyberPatient (CP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combination of textbook and CAI (CP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Textbook for self-instruction
Number of subjects: 59

Group type: COMPARATOR
Intervention: No learning (Group‐4)
Number of subjects: 59
Study: 11320358

Group type: EXPERIMENTAL
Intervention: 80 mg/d atorvastatin
Number of subjects: 600

Group type: COMPARATOR
Intervention: 40 mg/d pravastatin
Number of subjects: 600
Study: 9227718

Group type: EXPERIMENTAL
Intervention: Pranlukast 337.5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pranlukast 225 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pranlukast (both doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8424425

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg tid
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg qid
Number of subjects: 629

Group type: COMPARATOR
Intervention: Ranitidine 300 mg hs
Number of subjects: 629
Study: 3317345

Group type: EXPERIMENTAL
Intervention: Recombinant yeast-derived hepatitis B vaccine (2.5, 5, 10, or 20 micrograms)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Recombinant yeast-derived hepatitis B vaccine (20 micrograms booster)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine (20 micrograms)
Number of subjects: 220
Study: 31888741

Group type: EXPERIMENTAL
Intervention: Group-based body psychotherapy (BPT) with smartphone-triggered bodily intervention for 5 weeks, 6 days a week.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Group-based body psychotherapy (BPT) with smartphone-triggered control intervention for 5 weeks, 6 days a week.
Number of subjects: 88
Study: 28846481

Group type: EXPERIMENTAL
Intervention: HA 0.15% and DQS 3% (Group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HA and Liposic EDO Gel (Group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HA, DQS, and Liposic EDO Gel (Group 3)
Number of subjects: 0
Study: 25533398

Group type: EXPERIMENTAL
Intervention: Inhibitors of histone deacetylases (HDACi)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CMV promoter
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Heterologous expression cassettes targeted into two chromosomal sites using RMCE
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unrelated promoter
Number of subjects: 100
Study: 25623561

Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 63
Study: 22139545

Group type: EXPERIMENTAL
Intervention: Oral Fructus bruceae oil (20 mL, 3 times per day for 12 weeks) combined with radiotherapy (60‐65 Gy, 6‐7 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 80
Study: 19469786

Group type: EXPERIMENTAL
Intervention: PGE₁‐EE (maximum 1000 μg) applied transdermally using an adhesive foil patch
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (5 μg PGE₁‐EE)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PGE₁‐EE
Number of subjects: 34
Study: 28095541

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CO2 ablative fractional resurfacing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined treatment with pulsed dye laser and CO2 ablative fractional resurfacing
Number of subjects: 25

Group type: COMPARATOR
Intervention: CO2 ablative fractional resurfacing on the same day of surgery
Number of subjects: 25
Study: 15478785

Group type: EXPERIMENTAL
Intervention: Trager treatment group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 33

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 33
Study: 11875895

Group type: EXPERIMENTAL
Intervention: Treatment in a rehabilitation centre in Tenerife for four weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Treatment in two similar centres in Norway for four weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Ordinary health care programme (Control group)
Number of subjects: 88
Study: 9558553

Group type: EXPERIMENTAL
Intervention: Demineralized freeze‐dried bone allograft with titanium-reinforced expanded polytetrafluoroethylene membranes in Group A
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Autogenous bone chips with titanium-reinforced expanded polytetrafluoroethylene membranes in Group B
Number of subjects: 20
Study: 8179148

Group type: EXPERIMENTAL
Intervention: Crystalloid priming solution
Number of subjects: 19

Group type: COMPARATOR
Intervention: Colloid priming solution
Number of subjects: 19
Study: 3117566

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of triglyceride emulsions (LCT; MCT/LCT)
Number of subjects: 0
Study: 31087175

Group type: EXPERIMENTAL
Intervention: Mobile device app for postoperative education and self-assessment of recovery
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard written education (control)
Number of subjects: 97
Study: 30813926

Group type: EXPERIMENTAL
Intervention: Tailored 12-week strength and balance Exergame programme
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care (physiotherapy advice and leaflet)
Number of subjects: 106
Study: 29273467

Group type: EXPERIMENTAL
Intervention: Peppermint oil capsules (Colpermin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25668012

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 13339

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 13339

Group type: EXPERIMENTAL
Intervention: Combined (Ultrasound + Mammography)
Number of subjects: 13339
Study: 24064780

Group type: EXPERIMENTAL
Intervention: Mental module for workers' health surveillance, including screening for work functioning impairments and mental health complaints.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 21333457

Group type: EXPERIMENTAL
Intervention: Extensive rearing system (Churra breed)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intensive rearing system
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Churra breed
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Castellana breed
Number of subjects: 24
Study: 19342295

Group type: EXPERIMENTAL
Intervention: 400mg modafinil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: modafinil
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 16965866

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (55 Gy/20 fractions/4 weeks)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Conventional radiation therapy (64 Gy/32 fractions/6.5 weeks)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Both hypofractionated and conventional schedules
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Number of subjects: 217

Group type: COMPARATOR
Intervention: Conventional radiation therapy
Number of subjects: 217
Study: 14756266

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 10777469

Group type: EXPERIMENTAL
Intervention: New chemotherapeutic agents (paclitaxel, docetaxel, vinorelbine, gemcitabine, irinotecan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined-modality programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin and cisplatin-based combination regimens
Number of subjects: 0
Study: 8959593

Group type: EXPERIMENTAL
Intervention: STARS program (brief nurse consultations)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 138
Study: 1313340

Group type: EXPERIMENTAL
Intervention: Fraxiparine subcutaneously 400 anti‐Xa Institute Choay units/kg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Unfractionated heparin by continuous intravenous infusion
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fraxiparine subcutaneously 600 anti‐Xa Institute Choay units/kg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fraxiparine subcutaneously 900 anti‐Xa Institute Choay units/kg
Number of subjects: 101
Study: 3862405

Group type: EXPERIMENTAL
Intervention: Birthing chair (upright position)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Bed (recumbent position)
Number of subjects: 56
Study: 30843866

Group type: EXPERIMENTAL
Intervention: Blog intervention disseminated by mommy bloggers
Number of subjects: 798
Study: 29152672

Group type: EXPERIMENTAL
Intervention: Biosimilar filgrastim
Number of subjects: 98

Group type: COMPARATOR
Intervention: Original G-CSFs (lenograstim and pegfilgrastim)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Lenograstim
Number of subjects: 98
Study: 27381263

Group type: EXPERIMENTAL
Intervention: SheathLess Eaucath GC (Asahi Intecc, Aichi, Japan)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Standard GC (Medtronic Launcher; Minneapolis, MN)
Number of subjects: 233
Study: 23460503

Group type: EXPERIMENTAL
Intervention: Fesoterodine (4 mg, with potential increase to 8 mg after 4 or 8 weeks)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Fesoterodine (double-blind treatment)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo (double-blind treatment)
Number of subjects: 654
Study: 22238574

Group type: EXPERIMENTAL
Intervention: TAU+FT (Treatment as Usual plus Family Therapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TAU+FT
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 60
Study: 20163387

Group type: EXPERIMENTAL
Intervention: Acamprosate treatment
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Motivational therapy
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Subsyndromal anxiety (HAM-A 'Anxious Mood' item)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Presence of > or =1 psychiatric antecedent
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Lower pretreatment drinking intensity
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Baseline motivation to have abstinence as a goal
Number of subjects: 601
Study: 18687249

Group type: EXPERIMENTAL
Intervention: Defibrillation threshold (DFT) testing during ICD implantation
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Baseline DFT testing
Number of subjects: 811
Study: 15975299

Group type: EXPERIMENTAL
Intervention: Ganxian recipe (GXR) combined with lamivudine (LVD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: lamivudine (LVD) alone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ganxian recipe (GXR) alone
Number of subjects: 120
Study: 12925330

Group type: EXPERIMENTAL
Intervention: Nonparametric function in a semiparametric additive mixed model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonparametric functions in semiparametric additive mixed models for two groups
Number of subjects: 0
Study: 11314873

Group type: EXPERIMENTAL
Intervention: 20 mg citalopram orally 2 hours before ECT
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo orally 2 hours before ECT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9006785

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (500 mg) with standard breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (500 mg) with cholecystokinin (0.3 micrograms/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sustained-release theophylline (500 mg) under fasting conditions
Number of subjects: 12
Study: 1428302

Group type: COMPARATOR
Intervention: Isradipine (10 mg single dose)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Slow-release nicardipine (40 mg twice daily for six months)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 54
Study: 3970345

Group type: COMPARATOR
Intervention: Oxygen and oxygen-enriched air
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 0
Study: 31206056

Group type: EXPERIMENTAL
Intervention: PSI/reusable (PSR)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Single-use instrumentation (SUI)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Conventional/reusable instrumentation (CVR)
Number of subjects: 4
Study: 29073799

Group type: EXPERIMENTAL
Intervention: Mammography decision intervention (personalised risk estimates, varying by amount of information and format)
Number of subjects: 2465
Study: 25616935

Group type: EXPERIMENTAL
Intervention: Highest quintile of Carbohydrate Quality Index (CQI)
Number of subjects: 6542

Group type: EXPERIMENTAL
Intervention: Highest quintile of Mediterranean diet score
Number of subjects: 6542

Group type: EXPERIMENTAL
Intervention: Lowest quintile of Fat Quality Index (FQI)
Number of subjects: 6542

Group type: EXPERIMENTAL
Intervention: Higher CQI or Med-Diet score
Number of subjects: 6542

Group type: EXPERIMENTAL
Intervention: Lower FQI
Number of subjects: 6542
Study: 24929252

Group type: EXPERIMENTAL
Intervention: Community-based health management program for 18 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 100
Study: 23272551

Group type: EXPERIMENTAL
Intervention: Gray MTA (ProRoot MTA, Dentsply, Tulsa Dental)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: BioAggregate (Diadent Group International, Vancouver)
Number of subjects: 28
Study: 20840207

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Continuous and point-prevalence abstainers
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Non-abstainers
Number of subjects: 133
Study: 17671042

Group type: EXPERIMENTAL
Intervention: PAI1 4G/4G genotype
Number of subjects: 348

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 348
Study: 16128971

Group type: EXPERIMENTAL
Intervention: Additional support from volunteer breastfeeding counselors
Number of subjects: 720
Study: 11390120

Group type: EXPERIMENTAL
Intervention: Aerodiol 100 microg/day
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Aerodiol 200-600 microg/day
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Aerodiol 300 microg/day
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Aerodiol 400 microg/day
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Aerodiol 200 microg/day
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: COMPARATOR
Intervention: Oral estradiol 1 mg/day
Number of subjects: 420

Group type: COMPARATOR
Intervention: Oral estradiol 2 mg/day
Number of subjects: 420
Study: 9211475

Group type: EXPERIMENTAL
Intervention: Chronic Pain Grade questionnaire
Number of subjects: 400
Study: 8424908

Group type: EXPERIMENTAL
Intervention: Single agent cisplatinum
Number of subjects: 40

Group type: COMPARATOR
Intervention: Whole abdomino-pelvic moving strip radiotherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 40
Study: 3596167

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg) intravenously before tests
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg q.i.d., p.o.) for 1 month
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo intravenously before tests
Number of subjects: 8
Study: 2724196

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 66
Study: 3187

Group type: EXPERIMENTAL
Intervention: 100 mg oxytetracycline a day p.o. for 6 weeks after initial treatment with 1 g oxytetracycline a day p.o. for 1 week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of 100 mg oxytetracycline and 1.2 g sodiumbituminosulfonates a day p.o. for 6 weeks after initial treatment with 1 g oxytetracycline a day p.o. for 1 week
Number of subjects: 50

Group type: COMPARATOR
Intervention: 100 mg oxytetracycline a day p.o. for 6 weeks after treatment with combination therapy
Number of subjects: 50
Study: 30632918

Group type: EXPERIMENTAL
Intervention: Positive affect condition
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Negative affect condition
Number of subjects: 44

Group type: COMPARATOR
Intervention: Neutral affect condition
Number of subjects: 44
Study: 29149776

Group type: EXPERIMENTAL
Intervention: Nebulized 2.5 mg of salbutamol and 2.5 mL of 3% hypertonic saline solution for three consecutive 20-min periods
Number of subjects: 340

Group type: COMPARATOR
Intervention: Nebulized only salbutamol in the same dose and time as the intervention group
Number of subjects: 340
Study: 26068515

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (12 sessions within 48 hours of injury)
Number of subjects: 0
Study: 23795663

Group type: EXPERIMENTAL
Intervention: 22G needle
Number of subjects: 135

Group type: COMPARATOR
Intervention: 25G needle
Number of subjects: 135
Study: 21813427

Group type: EXPERIMENTAL
Intervention: Risperidone (up to 4 mg once daily)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 247
Study: 19661662

Group type: EXPERIMENTAL
Intervention: External birth defects screening
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: External congenital anomalies
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Musculoskeletal abnormalities
Number of subjects: 624
Study: 16432350

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 155

Group type: COMPARATOR
Intervention: Open gastric bypass
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 155
Study: 15693192

Group type: EXPERIMENTAL
Intervention: Nisoldipine extraction and analysis method using high-performance liquid chromatography-electrospray ionization mass spectrometry.
Number of subjects: 0
Study: 11378343

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy with additional radiotherapy or tamoxifen
Number of subjects: 141
Study: 9231451

Group type: EXPERIMENTAL
Intervention: Local alcohol policy interventions
Number of subjects: 0
Study: 8492058

Group type: EXPERIMENTAL
Intervention: Saturn-Ring used five times a week over an 8-week exercise program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional exercise alone
Number of subjects: 50
Study: 3101849

Group type: EXPERIMENTAL
Intervention: Vitamin A supplements (200,000 IU orally immediately and again the next day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Routine treatment alone (Control)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Vitamin A supplements (200,000 IU orally immediately and again the next day) in children aged under 2 years
Number of subjects: 180

Group type: COMPARATOR
Intervention: Routine treatment alone (Control) in children aged under 2 years
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups (regardless of allocation) in marasmic children
Number of subjects: 180